Hera Biotech, Inc. filed an amended Form D with the Securities and Exchange Commission on 2025-09-23.
Hera Biotech, Inc. filed an amended Form D notice of an exempt securities offering with the SEC on September 23, 2025. The filing reports $1.74M sold. Its industry group is Biotechnology. It names Somer Baburek (Executive Officer, Director), Paul Castella (Director), Wendy Smith (Director) (SEC Form D/A, September 23, 2025).
In its own words: “Diagnosing Endometriosis and Cervical Cancer—In Tissue.” (herabiotech.com, checked October 31, 2026)
Is this your company?
Sell to companies like Hera Biotech, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-09-23 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Hera Biotech, Inc.
Free to see. No signup.
More on the people and the money behind Hera Biotech, Inc., from the filings we hold.
Biotechnology raises by companies based in Texas, filed in September 2025, largest first.
Get an email when Hera Biotech, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Hera Biotech, Inc. raises, hires or launches. No email unless you switch it on.
Watch Hera Biotech, Inc. →Get the full cited report on Hera Biotech, Inc.
What the filing shows about Hera Biotech, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Hera Biotech, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Hera Biotech, Inc.'s address as 4725 College Park, Suite 200, San Antonio, TX 78249.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Hera Biotech, Inc. →
Amended on 2026-09-23: the amount sold changed from $796,328 to $1,736,823; the number of investors changed from 8 to 26. Figures on this page are from the amendment. Amended filing · Original filing
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Hera Biotech, Inc. is a registered filer with the SEC (CIK 1831293) and has filed since 2023-05-31. 4 filings are on record, the latest on 2026-09-23.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Hera Biotech, Inc.'s Form D of 2025-09-23 names Somer Baburek, Paul Castella, Wendy Smith and 2 more as its officers, directors or promoters.
Its new offerings report $1.06M sold across 2 offerings, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 766 filings in Biotechnology, totalled by week.
A portion of the proceeds will be used to pay compensation to the execution officers named in response to Item 3 above.
Somer Baburek is named as Executive Officer and Director on the Form D that Hera Biotech, Inc. filed with the SEC on 23 September 2025, one of 5 people that filing names.
Paul Castella is named as Director on the Form D that Hera Biotech, Inc. filed with the SEC on 23 September 2025, one of 5 people that filing names.
Wendy Smith is named as Director on the Form D that Hera Biotech, Inc. filed with the SEC on 23 September 2025, one of 5 people that filing names.
Neal Walsdorf, Jr. is named as Director on the Form D that Hera Biotech, Inc. filed with the SEC on 23 September 2025, one of 5 people that filing names.
Teo Tijerina is named as Director on the Form D that Hera Biotech, Inc. filed with the SEC on 23 September 2025, one of 5 people that filing names.
5 people named on the filing — 1 holding an executive role and 4 as directors only.
Named as of the 2025-09-23 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Hera Biotech, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Hera Biotech, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Hera Biotech, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Hera Biotech, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Hera Biotech, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Hera Biotech, Inc.. With no account yet, you sign up free and land on the result.
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/hera-biotech-inc-form-d-25000001